Related Experiment Video
Updated: Jul 28, 2025

Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Revitalizing myocarditis treatment through gut microbiota modulation: unveiling a promising therapeutic avenue
Jingyue Wang1,2, Xianfeng Zhang3, Xinyu Yang1,2
1Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Insights
Emerging research links gut microbiota to myocarditis, an inflammatory heart condition. Targeting gut bacteria may offer new therapeutic strategies for this growing concern.
Area of Science:
- Cardiology
- Microbiology
- Immunology
Background:
- Gut microbiota significantly influences cardiovascular diseases, including hypertension and atherosclerosis.
- Recent evidence implicates gut microbiota in the pathogenesis of myocarditis, an inflammatory heart condition causing myocardial damage.
- Myocarditis is a growing concern, particularly in young adults, and is linked to COVID-19 and vaccinations, yet therapeutic options remain limited.
Purpose of the Study:
- To review the gut-heart axis, gut microbiota-immune system interactions, and the association between myocarditis and the immune system.
- To explore the impact of gut microbiota and its metabolites on myocarditis development.
- To discuss current gut microbiota modulation strategies and future directions for targeting gut microbiota in myocarditis treatment.
Main Methods:
- Literature review focusing on the gut-heart axis.
- Analysis of studies linking gut microbiota, immune system, and myocarditis.
- Examination of therapeutic strategies for modulating gut microbiota.
Main Results:
- The gut-heart axis is a complex interplay influencing cardiovascular health.
- Gut microbiota and immune system dysregulation are implicated in myocarditis.
- Modulating gut microbiota presents a potential, yet underdeveloped, therapeutic avenue for myocarditis.
Conclusions:
- Targeting the gut microbiota-immune system-myocarditis axis offers a novel approach for myocarditis treatment.
- Further research is needed to establish gut microbiota as a viable therapeutic target for myocarditis.
- This review highlights the potential of gut microbiota modulation for managing myocarditis and its complications.
Abstract:
Numerous studies have demonstrated that gut microbiota plays an important role in the development and treatment of different cardiovascular diseases, including hypertension, heart failure, myocardial infarction, arrhythmia, and atherosclerosis. Furthermore, evidence from recent studies has shown that gut microbiota contributes to the development of myocarditis. Myocarditis is an inflammatory disease that often results in myocardial damage. Myocarditis is a common cause of sudden cardiac death in young adults. The incidence of myocarditis and its associated dilated cardiomyopathy has been increasing yearly. Myocarditis has gained significant attention on social media due to its association with both COVID-19 and COVID-19 vaccinations. However, the current therapeutic options for myocarditis are limited. In addition, little is known about the potential therapeutic targets of myocarditis. In this study, we review (1) the evidence on the gut-heart axis, (2) the crosslink between gut microbiota and the immune system, (3) the association between myocarditis and the immune system, (4) the impact of gut microbiota and its metabolites on myocarditis, (5) current strategies for modulating gut microbiota, (6) challenges and future directions for targeted gut microbiota in the treatment of myocarditis. The approach of targeting the gut microbiota in myocarditis is still in its infancy, and this is the study to explore the gut microbiota-immune system-myocarditis axis. Our findings are expected to pave the way for the use of gut microbiota as a potential therapeutic target in the treatment of myocarditis.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Myocarditis II: Clinical Features and Diagnostic Tests
Microorganisms in Medicine and Therapeutics
Endocarditis III: Medical Management

